查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2052057

核子醫學（放射性藥物）市場－市場趨勢、競爭格局與市場預測（2034 年）

Nuclear Medicine (Radiopharmaceuticals) - Market Insights, Competitive Landscape, and Market Forecast - 2034
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

核子醫學（放射性藥物）市場概述

  • 全球核醫（放射性藥物）市場預計將從 2025 年的 107.4692 億美元成長到 2034 年的 241.5235 億美元，展現出強勁且持續的成長動能。
  • 全球核醫（放射性藥物）市場預計在 2026 年至 2034 年的預測期內將以 9.50% 的年複合成長率成長。
  • 核子醫學（放射性藥物）市場的主要驅動力是癌症、心血管疾病和神經系統疾病等慢性病盛行率的上升，這增加了對先進診斷和治療解決方案的需求。此外，影像系統、放射性示蹤劑開發和治療診斷學的進步提高了診斷的準確性、安全性和患者療效。同時，醫療基礎設施的不斷改進、人們對疾病早期檢測意識的提高以及政府的支持措施也在持續推動核醫學檢測的普及。因此，這些因素共同推動了全球核醫學（放射性藥物）市場的成長。
  • 在核醫（放射性藥物）市場中營運的主要公司包括 Lantheus、Cardinal Health、GE Healthcare、Curium Pharma、Pharmalogic Holdings Corp.、Novartis、Cambridge Isotope Laboratories, Inc.、Sotera Health LLC、Bracco Imaging SpA、Jubilant Pharma Limited、NECSA Ltd.、ATor​​an Radio Ltd.、IBApes、NBayer StarApes、Northcker LLC、ATor​​an Radio, Ziegler、Telix Pharmaceuticals Limited、ITM Isotope Technologies Munich SE、Mallinckrodt PLC 和 ROTOP Pharmaka GmbH。
  • 由於北美地區慢性疾病（如癌症和心臟病）的高發生率，對先進診斷和治療方案的需求旺盛，預計該地區仍將是全球核醫學（放射性藥物）市場的主要區域。此外，該地區擁有完善的醫療基礎設施，並可方便地使用PET和SPECT掃描儀等尖端影像技術。同時，政府的支持性政策、積極的研發投入以及公眾對早期疾病檢測重要性的日益重視，持續推動了核醫學影像技術的應用，使北美成為全球最大的核子醫學市場。
  • 在核醫（放射性藥物）市場的產品類型細分市場中，預計到 2025 年，診斷產品細分市場中的單光子發射電腦斷層掃描 (SPECT) 領域的碘-125 類別將佔據最大的市場佔有率。

推動核醫（放射性藥物）市場成長的因素

  • 癌症、心血管疾病和其他慢性疾病發生率上升：癌症、心血管疾病和其他慢性疾病發生率的上升是核醫學（放射性藥物）市場的主要促進因素。隨著腫瘤、心臟病和神經系統疾病患者數量的增加，對先進診斷和治療方案的需求也不斷成長。核子醫學能夠實現早期精準檢測、器官功能成像和標靶治療，這些對於有效疾病管理至關重要。因此，慢性疾病負擔的加重直接推動了核醫檢查和放射性藥物的應用，從而支持了市場的穩定成長。
  • 標靶放射線治療需求成長：標靶放射線治療需求的成長是核醫（放射性藥物）市場的主要驅動力。標靶放射線治療（也稱為放射性配體療法）將放射性化合物直接輸送到癌細胞，最大限度地減少對健康組織的損傷，並提高治療的精確度。這種方法對神經內分泌腫瘤、前列腺癌以及某些類型的甲狀腺癌和肝癌等疾病尤其有效，因為傳統治療方法可能無效或引起嚴重的副作用。標靶放射線治療的日益普及得益於放射性藥物研發的進步、影像技術的改進以及臨床醫生和患者對其療效和安全性的認知不斷提高。隨著越來越多的醫院和專科癌症中心將這些治療方法納入其治療方案，對放射性藥物的需求持續成長，從而推動了全球核醫學市場的顯著成長。
  • PET和SPECT影像技術的廣泛應用是核醫學（放射性藥物）市場的主要驅動力。正子斷層掃描（PET）和單光子發射電腦斷層掃描（SPECT）等先進成像技術已被廣泛用於早期檢測、診斷和後續觀察包括癌症、心血管疾病和神經系統疾病在內的多種疾病。這些成像技術依賴特殊的放射性藥物，以高精度可視化體內代謝和生理過程。它們能夠提供準確、非侵入性且功能性的影像，因此在醫院和診斷中心廣泛使用。隨著對早期準確診斷的需求不斷成長，PET和SPECT成像技術的應用範圍也在不斷擴大，進一步推動了核醫學（放射性藥物）市場的成長。

核子醫學（放射性藥物）市場報告細分

本核醫學（放射性藥物）市場報告全面概​​述了全球核子醫學（放射性藥物）市場，重點分析了關鍵趨勢、成長要素、挑戰和機會。報告按產品類型、應用、最終用戶和地區對市場進行了細分，並深入剖析了北美、歐洲和亞太等主要市場的競爭格局、監管環境和市場動態。報告詳細介紹了主要產業參與企業及其最新產品創新，為企業提供關鍵數據，幫助其識別市場潛力、制定策略規劃，並掌握快速成長的核醫（放射性藥物）市場中新興的機會。

核子醫學和放射性藥物是醫學影像和治療領域的兩個專門分支，它們利用少量放射性物質（放射性藥物）來診斷和治療各種疾病。這些放射性化合物被注射到體內後，會在特定器官和組織中積聚，並釋放輻射。這種輻射可以透過PET和SPECT等成像系統進行檢測。這使得醫生能夠觀察器官功能，及早發現異常情況，並監測疾病進展。除了用於診斷外，某些放射性藥物還用於標靶治療，例如治療癌症、甲狀腺疾病和一些神經系統疾病。

核子醫學（放射性藥物）市場正經歷顯著成長，這主要得益於幾個關鍵因素。其中一個主要促進因素是慢性疾病（包括癌症和心血管疾病）的盛行率上升，這增加了對先進診斷和治療解決方案的需求。此外，對標靶放射治療的需求不斷成長也推動了市場擴張，因為放射性藥物能夠將輻射精確地輸送到病變細胞，同時最大限度地減少對周圍健康組織的損傷。另外，正子斷層掃描（PET）和單光子發射電腦斷層掃描（SPECT）等先進影像技術的日益普及，透過提供詳細的功能影像，提高了疾病的檢測和監測能力。這些因素共同推動了核醫影像技術的廣泛應用，進而促進了核子醫學（放射性藥物）市場的成長。

核子醫學（放射性藥物）市場的最新市場動態和趨勢是什麼？

核子醫學（放射性藥物）市場正經歷強勁成長，其促進因素包括癌症和心血管疾病的盛行率上升、對標靶放射治療的需求增加，以及正子斷層掃描（PET）和單光子發射電腦斷層掃描（SPECT）等先進影像技術的廣泛應用。

根據健康指標與評估研究所 (IHME, 2025) 的數據，2023 年全球心血管疾病 (CVD) 的失能調整後存活年(DALY) 為 4.37 億。

心血管疾病（CVD）是全球發病率和死亡率的主要原因之一，因此對精準診斷、風險評估和治療監測的需求顯著增加。核子醫學成像技術，例如使用PET和SPECT掃描進行心肌灌注顯像，使醫生能夠評估心臟血流、檢測冠狀動脈阻塞、評估心肌功能並識別氧供減少的區域。放射性藥物，包括基於Technetium-99m（Tc-99m）的示蹤劑和其他心臟影像劑，被廣泛用於冠狀動脈疾病、心肌缺血和心臟衰竭的診斷，從而顯著促進了核子醫學（放射性藥物）市場的成長。

此外，根據國際癌症研究機構（IARC，2026）的數據，2025年全球甲狀腺癌新病例估計為86.3萬例，預計到2045年將達到107萬例。同一資訊來源估計，2025年攝護腺癌新發病例將達157萬例，預計2045年將增加至263萬例。這些癌症通常需要先進的核子醫學掃描術診斷和標靶放射治療來進行準確診斷、分期和監測治療進展。在甲狀腺癌中，放射性碘等放射性藥物被廣泛用於診斷影像檢查和標靶治療。同樣，在前列腺癌中，使用前列腺特異性示踪劑的正電子發射斷層掃描（PET）等成像技術有助於檢測腫瘤轉移和製定有效的治療方案，從而推動了核醫學（放射性藥物）市場的成長。

然而，產品研發活動的增加進一步推動了整個核醫/放射性藥物市場的發展。例如，2025年3月，Telix Pharmaceuticals Limited宣布，美國食品藥物管理局（FDA）已批准其Gozellix®（TLX007-CDx，鎵-68[ 核准 ]戈澤肽注射液的製備試劑盒）的新藥認證申請（NDA），Gozellix®是一種用於前列腺癌的新一代PSMA-PET顯像劑。

因此，由於上述因素，預計從 2026 年到 2034 年的預測期內，整個核子醫學（放射性藥物）市場將擴張。

然而，核子醫學（放射性藥物）的發展受到許多挑戰的限制，包括許多放射性同位素半衰期短，難以儲存和運輸，以及需要在醫療機構附近建立生產設施。此外，迴旋加速器、PET/SPECT掃描儀和輻射屏蔽設施等專用基礎設施高成本，限制了許多醫院的應用。嚴格的法規和輻射安全要求進一步增加了放​​射性藥物的生產、處理和核准的複雜性。此外，對輻射暴露的擔憂、熟練專業人員的短缺以及醫用同位素偶爾的供不應求也限制了核子醫學技術在臨床環境中的廣泛應用。

核子醫學（放射性藥物）市場細分分析

核子醫學（放射性藥物）市場：按產品類型、應用、最終用戶和地區分類

核子醫學（放射性藥物）市場區域分析

北美核子醫學（放射性藥物）市場趨勢

預計到2025年，北美將佔據該地區核醫（放射性藥物）市場最大的佔有率，達到42%。這一主導地位歸因於癌症、心血管疾病和其他與生活方式改變和過度食用加工食品相關的慢性疾病發生率的上升。此外，當地企業的存在以及易患慢性疾病的老年人口的成長，也進一步鞏固了該地區的市場地位。

根據美國疾病管制與預防中心（CDC）的數據顯示，2024年美國約有80.5萬人罹患心肌梗塞。該機構也估計，到2050年，美國將有約1,210萬人患有心房顫動（心房顫動）。這些心血管疾病需要精準診斷、風險評估和持續監測心臟功能，而正子斷層掃描（PET）、單光子發射電腦斷層掃描（SPECT）和心肌灌注掃描等核子醫學掃描術診斷技術在其中發揮著至關重要的作用。放射性藥物是這些影像技術不可或缺的一部分，能夠實現受損心肌組織的非侵入性檢測、血流評估和心律不整的診斷。對先進心臟影像的日益依賴正在推動核醫學（放射性藥物）市場的成長。

此外，根據帕金森氏症基金會主導的一項2022年研究，美國每年約有9萬人被診斷出患有帕金森氏症。該研究也預測，到2030年，美國將有約120萬人罹患帕金森氏症。正子斷層掃描（PET）和單光子發射電腦斷層掃描（SPECT）等核子醫學掃描術診斷技術在檢測多巴胺轉運體活性和評估腦部功能方面發揮著至關重要的作用。這些檢查中使用的放射性藥物使臨床醫生能夠觀察神經元喪失情況，並以非侵入性方式監測疾病進展。隨著全球帕金森氏症患者人數的增加，對這些先進診斷工具的需求也在成長，從而推動了核醫學（放射性藥物）市場的成長。

然而，產品研發活動的增加進一步推動了整個核醫/放射性藥物市場的發展。例如，2024年4月，諾華公司的放射性配體療法Lutathera®獲得美國食品藥物管理局（FDA）批准，成為第一個專門用於治療兒童核准和胰臟神經內分泌腫瘤的藥物。

因此，預計上述所有因素將在預測期內推動北美核醫學（放射性藥物）市場的發展。

歐洲核子醫學（放射性藥物）市場趨勢

由於癌症、心血管疾病和神經退化性疾病的盛行率不斷上升，對早期診斷的需求不斷成長，以及PET和SPECT等先進影像技術被引入以進行準確、非侵入性的疾病檢測和監測，歐洲核醫學（放射性藥物）市場正在成長。

根據經濟合作暨發展組織（OECD）的數據，2022年歐洲約有6,200萬人罹患心血管疾病。準確診斷和監測心肌梗塞、冠狀動脈疾病和心律不整等心臟疾病需要先進的影像技術，例如正子斷層掃描（PET）、單光子發射電腦斷層掃描（SPECT）和心肌灌注掃描。放射性藥物在這些檢查中發揮著至關重要的作用，它們能夠對血流進行非侵入性評估、檢測受損的心肌組織並評估心臟功能，從而推動了核醫學（放射性藥物）市場的成長。

此外，根據國際癌症研究機構（IARC）的數據，2025年歐洲新增肝癌病例估計為78,600例，預計到2045年將達到75,500例。甲狀腺癌的診斷、分期和治療高度依賴核子醫學掃描術診斷技術，例如PET（正子斷層掃描）和SPECT（單光子發射電腦斷層掃描），以及使用放射性碘的放射性同位素療法。放射性藥物對於檢測惡性甲狀腺組織、監測轉移和實施標靶治療至關重要，從而實現精準且非侵入性的疾病管理。對核子醫學日益成長的依賴正在推動放射性藥物市場的擴張。

然而，產品研發活動的增加進一步推動了整個核醫/放射性藥物市場的發展。例如，2024年11月，Eckert & Ziegler Radiopharma GmbH公司獲得了歐盟委員會對其專有的無載體鎦-177（Theralugand®）的核准。

因此，預計上述所有因素將在預測期內推動歐洲核醫學（放射性藥物）市場的發展。

亞太地區核子醫學（放射性藥物）市場趨勢

亞太地區的核醫學（放射性藥物）市場正在擴張，其促進因素包括癌症、心血管疾病和神經退化性疾病發病率的上升、醫療保健成本的增加、診斷基礎設施的改善以及先進成像技術和放射性藥物療法的廣泛應用。

根據國際癌症研究機構（IARC）的數據，日本2025年甲狀腺癌新病例數預計為16,400例，預計到2045年將達到15,100例。甲狀腺癌的診斷和治療主要採用核子醫學掃描術診斷技術，例如PET和SPECT，以及放射性同位素療法，包括放射性碘療法。放射性藥物在輔助檢測惡性組織、監測轉移和實施標靶治療發揮重要作用，推動了核醫學（放射性藥物）市場的成長。

因此，由於上述因素，預計核醫（放射性藥物）市場將在全部區域擴張。

核子醫學（放射性藥物）市場的主要參與者有哪些？

以下是核子醫學（放射性藥物）市場的主要參與者。這些公司通常佔據最大的市場佔有率，並對行業趨勢產生影響。

  • Lantheus
  • Cardinal Health
  • GE Healthcare
  • Curium Pharma
  • Pharmalogic Holdings Corp.
  • Novartis
  • CambridgeIsotope Laboratories, Inc.
  • Sotera health LLC
  • Bracco Imaging SpA
  • Jubilant Pharma Limited
  • NECSA Ltd.
  • IBA Radiopharma Solutions
  • Bayer AG
  • Norgine
  • NorthStar Medical Radioisotopes, LLC
  • Eckert & Ziegler
  • Telix Pharmaceuticals Limited
  • ITM Isotope Technologies Munich SE
  • Mallinckrodt PLC
  • ROTOP Pharmaka GmbH
  • 其他

競爭格局如何影響核子醫學（放射性藥物）市場？

核子醫學（放射性藥物）市場的競爭格局由多家全球和區域性大型企業主導，這些企業透過產品創新、策略聯盟和地理擴張展開競爭。 GE醫療、拜耳、諾華/先進加速器應用、Jubilant生命科學和Curium製藥等領導企業正大力投資研發，以推出用於診斷和治療的新型放射性藥物。此外，併購和合作也使這些企業能夠擴展產品系列、加強分銷網路並進入新市場，尤其是在新興市場。同時，新型放射性示蹤劑的監管核准以及PET、SPECT和治療診斷學等影像技術的不斷進步，正在推動創新和差異化競爭。小規模的專業公司也正帶著其利基放射性藥物進入市場，進一步促進市場區隔與創新。

因此，競爭環境正在推動技術的快速進步、產品線的擴展和獲取途徑的改善，這些因素共同塑造了全球核醫學（放射性藥物）市場的成長軌跡。

核子醫學（放射性藥物）市場的最新發展趨勢

  • 2025 年 3 月，Telix Pharmaceuticals Limited 宣布，美國食品藥物管理局(FDA) 已批准其 Gozellix(R)（TLX007-CDx，鎵-68[68Ga]核准注射的製備試劑盒）的新藥新藥認證(NDA)，該產品是該公司用於前列腺癌的下一代 PSMA-PET 成像劑。

核子醫學（放射性藥物）市場細分

  • 核子醫學（放射性藥物）市場按產品類型分類的趨勢
  • 診斷產品
  • 單光子發射電腦斷層掃描（SPECT）
  • Technetium-99m
  • 碘-125
  • 氙-133
  • 其他
  • 正子斷層掃描（PET）
  • 氟-18
  • 碳-11
  • 鎵-68
  • 其他
  • 治療產品
  • α粒子發射材料
  • 砈-211
  • 錒-225
  • 鉛-212
  • 其他
  • BETA射線放射體
  • 鎦-177
  • 碘-131
  • 釔-90
  • 其他
  • 近距離放射治療
  • 核子醫學（放射性藥物）應用引起的輻射暴露
  • 循環系統
  • 神經病學
  • 腫瘤學
  • 其他
  • 核子醫學（放射性藥物）中最終使用者的輻射暴露
  • 醫院
  • 診斷中心
  • 其他
  • 核子醫學（放射性藥物）的區域趨勢
  • 北美核子醫學（放射性藥物）市場
  • 美國核子醫學（放射性藥物）市場
  • 加拿大核醫學（放射性藥物）市場
  • 墨西哥核子醫學（放射性藥物）市場
  • 歐洲核子醫學（放射性藥物）市場
  • 英國核子醫學（放射性藥物）市場
  • 德國核子醫學（放射性藥物）市場
  • 法國核子醫學（放射性藥物）市場
  • 義大利核子醫學（放射性藥物）市場
  • 西班牙核子醫學（放射性藥物）市場
  • 其他歐洲核子醫學（放射性藥物）市場
  • 亞太地區核子醫學（放射性藥物）市場。
  • 中國核子醫學（放射性藥物）市場
  • 日本核子醫學（放射性藥物）市場
  • 印度核子醫學（放射性藥物）市場
  • 澳洲核子醫學（放射性藥物）市場
  • 韓國核子醫學（放射性藥物）市場
  • 亞太地區其他核子醫學（放射性藥物）市場
  • 其他地區的核子醫學（放射性藥物）市場
  • 南美洲核子醫學（放射性藥物）市場
  • 中東核子醫學（放射性藥物）市場
  • 非洲核子醫學（放射性藥物）市場

影響分析

人工智慧驅動的創新與應用：

人工智慧驅動的創新技術正在改變核子醫學（放射性藥物）市場，顯著提升診斷準確性和營運效率。人工智慧演算法正被整合到PET和SPECT掃描儀等成像系統中，從而改善影像重建、降低雜訊並提高異常檢測的準確性，使臨床醫生能夠更早識別疾病。此外，人工智慧還促進了工作流程的自動化，包括患者預約管理、放射性藥物劑量計算和品管，從而減少人為錯誤並最佳化資源利用。人工智慧在治療診斷學（整合治療和診斷醫學）中的應用，透過分析大規模資料集預測患者對放射性藥物療法（例如標靶癌症治療）的反應，從而實現個人化治療方案的發展。人工智慧的整合也為藥物研發提供支持，幫助製造商設計更有效的放射性示踪劑並加快監管核准。因此，人工智慧主導的創新正在改善臨床結果、降低營運成本並擴大核醫學影像的應用範圍，從而促進核醫學（放射性藥物）市場的整體成長和效率提升。

美國關稅對核子醫學（放射性藥物）市場的影響分析：

美國對進口醫療設備和放射性藥物徵收的關稅對核醫學（放射性藥物）市場產生了重大影響。原料、同位素和診斷試劑盒進口關稅的提高，推高了依賴全球供應鏈的國內製造商的生產成本。此外，這些成本上漲通常會轉嫁給醫療服務提供者，這可能會限制對成本敏感的醫院和診所採用先進的核子醫學掃描術診斷和治療方法。同時，關稅也可能促使企業投資本地生產和供應鏈多元化，以減少對進口的依賴。這可能會增加初始資本投入，但有助於提高市場的長期穩定性。因此，雖然關稅可能會因價格上漲而暫時減緩市場成長，但也會刺激策略性在地化和創新，從而重塑美國核子醫學（放射性藥物）市場的競爭格局和商業環境。

這項分析能為客戶帶來哪些好處？

  • 成本管理：透過了解關稅趨勢，客戶可以預測成本上漲，並據此調整定價策略，以確保盈利。
  • 供應鏈最佳化：透過尋找替代供應商並使其供應鏈多元化，客戶可以減少對高關稅地區的依賴，並增強業務永續營運。
  • 監管合規：專家指導幫助客戶應對不斷變化的法規環境，從而保持合規並避免潛在的法律挑戰。
  • 策略規劃：深入了解關稅的影響，使客戶能夠就製造地、夥伴關係和打入市場策略做出明智的決策。

核子醫學（放射性藥物）市場報告要點

  • 目前核子醫學（放射性藥物）市場規模分析（2025 年）及 8 年市場預測（2026-2034 年）
  • 過去三年發生的主要產品和技術開發、併購、合作和合資企業
  • 在核醫學（放射性藥物）市場佔據主導地位的領先公司。
  • 核子醫學（放射性藥物）市場為其他競爭者提供了各種機會。
  • 哪些細分市場在2025年表現最佳？這些細分市場在2034年又會呈現哪些趨勢？
  • 目前哪些地區或國家在核子醫學（放射性藥物）市場表現最佳？
  • 企業應重點關注哪些地區和國家，以尋求核醫（放射性藥物）市場的未來成長機會？

關於核子醫學（放射性藥物）市場的常見問題

1. 核子醫學（放射性藥物）市場的成長率是多少？

  • 預計從 2026 年到 2034 年的預測期內，核醫（放射性藥物）市場將以 9.50% 的年複合成長率成長。

2. 核子醫學/放射性藥物市場是什麼？

  • 全球核醫學（放射性藥物）市場預計將從 2025 年的 107.4692 億美元成長到 2034 年的 241.5235 億美元，反映出強勁且持續的成長。

3. 哪個地區在核子醫學（放射性藥物）市場中佔據最大的市場佔有率？

  • 由於生活方式改變和加工食品消費量增加，癌症、心血管疾病和慢性疾病的發生率不斷上升，預計北美將成為全球核子醫學（放射性藥物）市場的主要驅動力。此外，美國擁有眾多本土企業，老年人口不斷成長，以及對放射性藥物有利的報銷政策，這些都是支撐該地區市場成長的關鍵因素。

4. 核子醫學（放射性藥物）市場的成長要素為何？

  • 由於癌症、心血管疾病和慢性疾病的發生率不斷上升，以及人口老化，核子醫學（放射性藥物）市場正經歷強勁成長。此外，對影像導引診斷和手術的需求不斷成長、豐富的創新產品線以及政府的支持，都在推動市場滲透。同時，持續的研發活動、監管核准、新產品上市以及主要行業參與者的存在，進一步加速了市場擴張，使核子醫學成為現代醫學不可或缺的一部分。

5. 核子醫學（放射性藥物）市場的主要公司有哪些？

  • 核子醫學（放射性藥物）市場的主要參與者包括 Lantheus、Cardinal Health、GE Healthcare、Curium Pharma、Pharmalogic Holdings Corp.、Novartis、Cambridge Isotope Laboratories, Inc.、Sotera Health LLC、Bracco Imaging SpA、Jubilant Pharma Limited、NECSA Ltd.、A Starphk、IBA​​Yk Ziegler、Telix Pharmaceuticals Limited、ITM Isotope Technologies Munich SE、Mallinckrodt PLC 和 ROTOP Pharmaka GmbH。

目錄

第1章：核子醫學（放射性藥物）市場報告概述

  • 調查範圍
  • 市場區隔
  • 市場預期

第2章：核子醫學（放射性藥物）市場執行摘要

  • 市場概覽

第3章：核子醫學（放射性藥物）市場關鍵因素分析

  • 驅動核子醫學（放射性藥物）市場的因素
    • 癌症、心血管疾病和其他慢性疾病的發生率不斷上升
    • 對標靶放射線治療的需求增加
    • PET和SPECT影像技術的廣泛應用
  • 阻礙核子醫學（放射性藥物）市場發展的因素與挑戰。
    • 半衰期短、有輻射暴露風險、基礎建設及營運成本高。
    • 嚴格的監管核准流程
  • 核子醫學（放射性藥物）市場的機會
    • 研發機會增多，以及有前景的產品正在研發中。

第4章：影響分析

  • 人工智慧驅動的創新和應用
  • 美國關稅影響分析

第5章：監理分析

  • 美國
  • 歐洲
  • 日本
  • 中國

第6章：波特五力模型在核醫（放射性藥物）市場競爭力分析的應用

第7章：核子醫學（放射性藥物）市場評估

  • 依產品類型
    • 診斷產品
    • 治療藥物
  • 透過使用
    • 心臟病學
    • 神經病學
    • 腫瘤學
    • 其他
  • 最終用戶
    • 醫院
    • 診斷中心
  • 按地區
    • 北美洲
    • 歐洲
    • 亞太地區
    • 其他地區

第8章 競爭情勢

第9章 核子醫學（放射性藥物）市場：公司與產品概述

  • Lantheus
  • Cardinal Health
  • GE Healthcare
  • Curium Pharma
  • Pharmalogic Holdings Corp.
  • Novartis
  • Cambridge Isotope Laboratories
  • Sotera Health
  • Bracco Imaging SpA
  • Jubilant Pharma Ltd.
  • NECSA Ltd.
  • IBA Radiopharma Solutions
  • Bayer AG
  • Norgine
  • NorthStar Medical Radioisotopes, LLC
  • Eckert & Ziegler
  • Telix Pharmaceuticals
  • ITM Isotope Technologies Munich SE
  • Mallinckrodt PLC
  • ROTOP Pharmaka GmbH

第10章：KOL的視角

第11章 專案方法

第12章：關於 DelveInsight

第13章 免責聲明與聯絡方式

Product Code: DIMDCL0608

Nuclear Medicine (Radiopharmaceuticals) Market Summary

  • The global nuclear medicine (radiopharmaceuticals) market is expected to increase from USD 10,746.92 million in 2025 to USD 24,152.35 million by 2034, reflecting strong and sustained growth.
  • The global nuclear medicine (radiopharmaceuticals) market is growing at a CAGR of 9.50% during the forecast period from 2026 to 2034.
  • The nuclear medicine (radiopharmaceuticals) market is primarily driven by the growing prevalence of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions, which increases the demand for advanced diagnostic and therapeutic solutions. Additionally, technological advancements in imaging systems, radiotracer development, and theranostics have improved accuracy, safety, and patient outcomes. Moreover, expanding healthcare infrastructure, rising awareness about early disease detection, and favorable government initiatives consistently support the adoption of nuclear medicine procedures. Consequently, these factors collectively fuel the growth of the global nuclear medicine (radiopharmaceuticals) market.
  • The leading companies operating in the nuclear medicine (radiopharmaceuticals) market include Lantheus, Cardinal Health, GE Healthcare, Curium Pharma,Pharmalogic Holdings Corp., Novartis, Cambridge Isotope Laboatories, Inc., Sotera Health LLC, Bracco Imaging SpA, Jubilant Pharma Limited, NECSA Ltd., IBA Radiopharma Solutions, Bayer AG, Norgine, NorthStar Medical Radioisotopes, LLC, Eckert & Ziegler, Telix Pharmaceuticals Limited, ITM Isotope Technologies Munich SE, Mallinckrodt PLC, ROTOP Pharmaka GmbH and others.
  • North America is expected to remain a leading region in the global nuclear medicine (radiopharmaceuticals) market due to a high prevalence of chronic diseases such as cancer and heart conditions, which drives demand for advanced diagnostic and therapeutic solutions. Additionally, the region has well-developed healthcare infrastructure and access to cutting-edge imaging technologies like PET and SPECT scanners. Moreover, supportive government policies, strong research and development activities, and increasing public awareness about early disease detection consistently boost the adoption of nuclear medicine procedures, making North America the largest market globally.
  • In the product type segment of the nuclear medicine (radiopharmaceuticals) market, within diagnostic products segment, the iodine-125 category under single photon emission computed tomography (SPECT) is estimated to account for the largest market share in 2025.

Factors Contributing to the Growth of the Nuclear Medicine (Radiopharmaceuticals) Market

  • Rising prevalence of cancer, cardiovascular and other chronic diseases: The rising prevalence of cancer, cardiovascular, and other chronic diseases is a key driver for the nuclear medicine (radiopharmaceuticals) market. As the number of patients with conditions such as oncological, cardiac, and neurological disorders increases, the demand for advanced diagnostic and therapeutic solutions grows. Nuclear medicine enables early and accurate detection, functional imaging of organs, and targeted treatment, which is critical for effective disease management. Consequently, the increasing burden of chronic diseases directly boosts the adoption of nuclear medicine procedures and radiopharmaceuticals, supporting the market's steady growth.
  • Increasing demand for targeted radiotherapy : The increasing demand for targeted radiotherapy is a key driver of the nuclear medicine (radiopharmaceuticals) market. Targeted radiotherapy, also known as radioligand therapy, involves delivering radioactive compounds directly to cancerous cells, minimizing damage to healthy tissues and improving treatment precision. This approach is particularly effective for conditions such as neuroendocrine tumors, prostate cancer, and certain types of thyroid and liver cancers, where conventional therapies may be less effective or cause significant side effects. The growing adoption of targeted radiotherapy is fueled by advancements in radiopharmaceutical development, improved imaging techniques, and increasing awareness among clinicians and patients about its efficacy and safety. As more hospitals and specialized cancer centers integrate these therapies into their treatment protocols, the demand for radiopharmaceuticals continues to rise, driving significant growth in the global nuclear medicine market.
  • Growing adoption of PET and SPECT Imaging : The growing adoption of PET and SPECT imaging is a major driver of the nuclear medicine (radiopharmaceuticals) market. Advanced imaging technologies such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) are widely used for the early detection, diagnosis, and monitoring of various diseases, including cancer, cardiovascular disorders, and neurological conditions. These imaging techniques rely on specialized radiopharmaceuticals to visualize metabolic and physiological processes within the body with high precision. Their ability to provide accurate, non-invasive, and functional imaging has increased their adoption in hospitals and diagnostic centers. As the demand for early and precise diagnosis continues to rise, the use of PET and SPECT imaging is expanding, thereby driving the growth of the nuclear medicine (radiopharmaceuticals) market.

Nuclear Medicine (Radiopharmaceuticals) Market Report Segmentation

This nuclear medicine (radiopharmaceuticals) market report offers a comprehensive overview of the global nuclear medicine (radiopharmaceuticals) market, highlighting key trends, growth drivers, challenges, and opportunities. It covers detailed market segmentation by Product Type (Diagnostic Products [Single Photon Emission Computed Tomography (SPECT) {Technetium-99m, Iodine-125, Xenon-133, and Others} and Positron Emission Tomography (PET) {Flourine-18, Carbon-11, Gallium-68, and Others}], and Therapeutic Products [Alpha Emitters {Astatine-211, Actinium-225, Lead-212, and Others}, Beta Emitters {Lutetium-177, Iodine-131, Yttrium-90, and Others}, and Brachytherapy]), Application (Cardiology, Neurology, Oncology, and Others), End-User (Hospitals, Diagnostic Centers, and Others), and Geography. The report provides valuable insights into the competitive landscape, regulatory environment, and market dynamics across major markets, including North America, Europe, and Asia-Pacific. Featuring in-depth profiles of leading industry players and recent product innovations, this report equips businesses with essential data to identify market potential, develop strategic plans, and capitalize on emerging opportunities in the rapidly growing nuclear medicine (radiopharmaceuticals) market.

Nuclear medicine and radiopharmaceuticals refer to a specialized field of medical imaging and therapy that uses small amounts of radioactive substances (radiopharmaceuticals) to diagnose and treat various diseases. These radioactive compounds are introduced into the body, where they accumulate in specific organs or tissues and emit radiation that can be detected using imaging systems such as PET or SPECT scanners. This enables physicians to visualize organ function, detect abnormalities at an early stage, and monitor disease progression. In addition to diagnosis, certain radiopharmaceuticals are also used in targeted treatments, particularly for conditions such as cancer, thyroid disorders, and some neurological diseases.

The nuclear medicine (radiopharmaceuticals) market is witnessing substantial growth due to several key factors. One of the major drivers is the increasing prevalence of chronic diseases, including cancer and cardiovascular diseases, which has increased the need for advanced diagnostic and therapeutic solutions. In addition, the rising demand for targeted radiotherapy is supporting market expansion, as radiopharmaceuticals enable precise delivery of radiation to diseased cells while minimizing damage to surrounding healthy tissues. Furthermore, the growing adoption of advanced imaging technologies, such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT), is enhancing disease detection and monitoring by providing detailed functional imaging. These factors collectively contribute to the increasing utilization of nuclear medicine procedures, thereby driving the growth of the nuclear medicine (radiopharmaceuticals) market.

What are the latest nuclear medicine (radiopharmaceuticals) market dynamics and trends?

The nuclear medicine (radiopharmaceuticals) market is witnessing strong growth driven by the rising prevalence of cancer and cardiovascular diseases, increasing demand for targeted radiotherapy, and the expanding use of advanced imaging technologies such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT).

According to the Institute for Health Metrics and Evaluation (2025), there were 437 million cardiovascular disease (CVD) disability-adjusted life years (DALYs) globally in 2023.

Cardiovascular diseases (CVDs), being a leading cause of morbidity and mortality globally, have significantly increased the demand for precise diagnosis, risk evaluation, and treatment monitoring. Nuclear medicine imaging techniques, such as myocardial perfusion imaging performed using PET and SPECT scans, enable physicians to evaluate blood flow to the heart, detect coronary artery blockages, assess heart muscle function, and identify areas with reduced oxygen supply. Radiopharmaceuticals, including technetium-99m-based tracers and other cardiac imaging agents, are widely used to diagnose conditions such as coronary artery disease, myocardial ischemia, and heart failure, thereby contributing significantly to the growth of the nuclear medicine (radiopharmaceuticals) market.

Moreover, according to the International Agency for Research on Cancer (2026), the estimated number of new thyroid cancer cases globally was 863,000 in 2025 and is projected to reach 1.07 million by 2045. As per the same source, the estimated number of new cases of prostate cancer was 1.57 million in 2025 and is projected to increase to 2.63 million by 2045. These cancers often require advanced nuclear imaging and targeted radiotherapy for accurate diagnosis, staging, and treatment monitoring. In thyroid cancer, radiopharmaceuticals such as radioactive iodine are widely used for both diagnostic imaging and targeted treatment of cancerous thyroid tissue. Similarly, in prostate cancer, imaging techniques like positron emission tomography (PET) using prostate-specific tracers help detect tumor spread and support effective treatment planning, thereby driving the growth of the nuclear medicine (radiopharmaceuticals) market.

However, the increase in product development activities is further boosting the overall market of nuclear medicine/ radiopharmaceuticals. For instance, in March 2025, Telix Pharmaceuticals Limited announced that the United States Food and Drug Administration (FDA) had approved its New Drug Application (NDA) for Gozellix(R) (TLX007-CDx, a kit for the preparation of gallium-68 [68Ga] gozetotide injection), Telix's next-generation PSMA-PET imaging agent for prostate cancer.

Thus, the factors mentioned above are expected to boost the overall market of nuclear medicine (radiopharmaceuticals) during the forecast period from 2026 to 2034.

However, the growth of nuclear medicine (radiopharmaceuticals) is restrained by several challenges, including the short half-life of many radioisotopes, which makes storage and transportation difficult and requires production facilities to be located near healthcare centers. In addition, the high cost of specialized infrastructure, such as cyclotrons, PET/SPECT scanners, and radiation-shielded facilities, limits adoption in many hospitals. Strict regulatory and radiation safety requirements further complicate the manufacturing, handling, and approval of radiopharmaceuticals. Moreover, concerns about radiation exposure, limited availability of skilled professionals, and occasional supply shortages of medical isotopes also restrict the wider use of nuclear medicine technologies in clinical practice.

Nuclear Medicine (Radiopharmaceuticals) Market Segment Analysis

Nuclear Medicine (Radiopharmaceuticals) Market by Product Type (Diagnostic Products [Single Photon Emission Computed Tomography (SPECT) {Technetium-99m, Iodine-125, Xenon-133, and Others} and Positron Emission Tomography (PET) {Flourine-18, Carbon-11, Gallium-68, and Others}], and Therapeutic Products [Alpha Emitters {Astatine-211, Actinium-225, Lead-212, and Others}, Beta Emitters {Lutetium-177, Iodine-131, Yttrium-90, and Others}, and Brachytherapy]), Application (Cardiology, Neurology, Oncology, and Others), End-User (Hospitals, Diagnostic Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

Nuclear Medicine (Radiopharmaceuticals) Market Regional Analysis

North America Nuclear Medicine (Radiopharmaceuticals) Market Trends

North America is expected to account for the highest proportion of 42% of the nuclear medicine (radiopharmaceuticals) market in 2025, out of all regions. This dominance is driven by the rising prevalence of cancer, cardiovascular, and other chronic diseases linked to lifestyle changes and high processed food consumption. Additionally, the presence of major local players and a growing geriatric population susceptible to chronic conditions further strengthens the market in the region.

According to the Centers for Disease Control and Prevention, in 2024, approximately 805,000 people in the United States experienced a heart attack. As per the same source, it was estimated that approximately 12.1 million people in the United States would have atrial fibrillation (AFib) by 2050. These cardiovascular conditions demand accurate diagnosis, risk evaluation, and ongoing monitoring of heart function, where nuclear imaging techniques such as PET (Positron Emission Tomography), SPECT (Single Photon Emission Computed Tomography), and myocardial perfusion scans play a vital role. Radiopharmaceuticals, integral to these imaging procedures, enable non-invasive detection of damaged heart tissue, assessment of blood flow, and evaluation of arrhythmias. This increasing reliance on advanced cardiac imaging is driving the growth of the nuclear medicine (radiopharmaceuticals) market.

Moreover, according to a 2022 study led by the Parkinson's Foundation, nearly 90,000 people were diagnosed with Parkinson's disease each year in the United States. The study also estimates that by 2030, approximately 1.2 million people in the U.S. will be living with Parkinson's disease. Nuclear imaging techniques such as PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Tomography) play a key role in detecting dopamine transporter activity and assessing brain function. Radiopharmaceuticals used in these scans allow clinicians to visualize neuronal loss and monitor disease progression non-invasively. As the number of Parkinson's patients increases globally, demand for these advanced diagnostic tools rises, thereby driving growth in the nuclear medicine (radiopharmaceuticals) market.

However, the increase in product development activities is further boosting the overall market of Nuclear medicine/ radiopharmeceuticals. For instance, in April 2024, Novartis' radioligand therapy Lutathera(R) was approved by the FDA as the first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors.

Thus, all the above-mentioned factors are anticipated to propel the market for nuclear medicine (radiopharmaceuticals) in North America during the forecast period.

Europe Nuclear Medicine (Radiopharmaceuticals) Market Trends

The nuclear medicine (radiopharmaceuticals) market in Europe is growing due to the rising prevalence of cancer, cardiovascular diseases, and neurodegenerative disorders, increasing demand for early diagnosis, and the adoption of advanced imaging technologies like PET and SPECT for accurate, non-invasive disease detection and monitoring.

According to the Organisation for Economic Co-operation and Development, in 2022, cardiovascular diseases affected an estimated 62 million people in Europe. Accurate diagnosis and monitoring of heart conditions, including heart attacks, coronary artery disease, and arrhythmias, rely on advanced imaging techniques such as PET (Positron Emission Tomography), SPECT (Single Photon Emission Computed Tomography), and myocardial perfusion scans. Radiopharmaceuticals play a crucial role in these procedures by enabling non-invasive assessment of blood flow, detection of damaged heart tissue, and evaluation of cardiac function, thereby driving the growth of the nuclear medicine (radiopharmaceuticals) market.

Additionally, according to the International Agency for Research on Cancer, the estimated number of new Liver Cancer cases in Europe was 78,600 in 2025, and it is projected to reach 75,500 by 2045. The diagnosis, staging, and treatment of Thyroid Cancer heavily depend on nuclear imaging techniques such as PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Tomography), along with radioisotope-based therapies like radioactive iodine. Radiopharmaceuticals are essential for detecting malignant thyroid tissue, monitoring metastasis, and delivering targeted therapy, allowing for precise and non-invasive disease management. This growing reliance on nuclear medicine is driving the expansion of the radiopharmaceuticals market.

However, the increase in product development activities is further boosting the overall market of nuclear medicine/ radiopharmaceuticals. For instance, in November 2024, Eckert & Ziegler Radiopharma GmbH received approval from the European Commission for its proprietary non-carrier-added Lutetium-177 chloride, Theralugand(R).

Hence, all the factors mentioned above are expected to drive the market for nuclear medicine (radiopharmaceuticals) in Europe during the forecast period.

Asia-Pacific Nuclear Medicine (Radiopharmaceuticals) Market Trends

The nuclear medicine (radiopharmaceuticals) market in the Asia-Pacific region is expanding, driven by the increasing incidence of cancer, cardiovascular, and neurodegenerative disorders, rising healthcare spending, enhanced diagnostic infrastructure, and wider adoption of advanced imaging techniques and radiopharmaceutical treatments.

According to the International Agency for Research on Cancer, the estimated number of new thyroid cancer cases in Japan was 16,400 in 2025 and is projected to reach 15,100 by 2045. Thyroid cancer diagnosis and treatment rely on nuclear imaging techniques like PET and SPECT, along with radioisotope therapies such as radioactive iodine. Radiopharmaceuticals help detect malignant tissue, monitor metastasis, and deliver targeted therapy, driving growth in the nuclear medicine (radiopharmaceuticals) market.

Thus, the factors mentioned above are expected to boost the market of nuclear medicine (radiopharmaceuticals) across the Asia-Pacific region.

Who are the major players in the nuclear medicine (radiopharmaceuticals) market?

The following are the leading companies in the nuclear medicine (radiopharmaceuticals) market. These companies collectively hold the largest market share and dictate industry trends.

  • Lantheus
  • Cardinal Health
  • GE Healthcare
  • Curium Pharma
  • Pharmalogic Holdings Corp.
  • Novartis
  • CambridgeIsotope Laboratories, Inc.
  • Sotera health LLC
  • Bracco Imaging SpA
  • Jubilant Pharma Limited
  • NECSA Ltd.
  • IBA Radiopharma Solutions
  • Bayer AG
  • Norgine
  • NorthStar Medical Radioisotopes, LLC
  • Eckert & Ziegler
  • Telix Pharmaceuticals Limited
  • ITM Isotope Technologies Munich SE
  • Mallinckrodt PLC
  • ROTOP Pharmaka GmbH
  • Others

How is the competitive landscape shaping the nuclear medicine (radiopharmaceuticals) market?

The competitive landscape of the nuclear medicine (radiopharmaceuticals) market is shaped by the presence of several global and regional key players competing through product innovation, strategic collaborations, and geographic expansion. Leading companies such as GE Healthcare, Bayer AG, Novartis/Advanced Accelerator Applications, Jubilant Life Sciences, and Curium Pharma are heavily investing in research and development to introduce new radiopharmaceuticals for both diagnostic and therapeutic applications. Additionally, mergers, acquisitions, and partnerships are enabling companies to expand their product portfolios, enhance distribution networks, and access new markets, particularly in emerging regions. Moreover, regulatory approvals for novel radiotracers and continuous advancements in imaging technologies like PET, SPECT, and theranostics are driving innovation and competitive differentiation. Smaller specialized firms are also entering the market with niche radiopharmaceuticals, increasing market fragmentation and innovation.

Consequently, the competitive environment is fostering rapid technological advancements, expanded product offerings, and improved accessibility, which together are shaping the growth trajectory of the global nuclear medicine (radiopharmaceuticals) market.

Recent Developmental Activities in the Nuclear Medicine (Radiopharmaceuticals) Market

  • In March 2025, Telix Pharmaceuticals Limited announced that the United States Food and Drug Administration (FDA) had approved its New Drug Application (NDA) for Gozellix(R) (TLX007-CDx, a kit for the preparation of gallium-68 [68Ga] gozetotide injection), Telix's next-generation PSMA-PET imaging agent for prostate cancer.

Nuclear Medicine (Radiopharmaceuticals) Market Segmentation

  • Nuclear Medicine (Radiopharmaceuticals) by Product Type Exposure
  • Diagnostic Products
  • Single Photon Emission Computed Tomography (SPECT)
  • Technetium-99m
  • Iodine-125
  • Xenon-133
  • Others
  • Positron Emission Tomography (PET)
  • Fluorine-18
  • Carbon-11
  • Gallium-68
  • Others
  • Therapeutics Products
  • Alpha Emitters
  • Astatine-211
  • Actinium-225
  • Lead-212
  • Others
  • Beta Emitters
  • Lutetium-177
  • Iodine-131
  • Yttrium-90
  • Others
  • Brachytherapy
  • Nuclear Medicine (Radiopharmaceuticals) Application Exposure
  • Cardiology
  • Neurology
  • Oncology
  • Others
  • Nuclear Medicine (Radiopharmaceuticals) End-Users Exposure
  • Hospitals
  • Diagnostic Centers
  • Others
  • Nuclear Medicine (Radiopharmaceuticals) Geography Exposure
  • North America Nuclear Medicine (Radiopharmaceuticals) Market
  • United States Nuclear Medicine (Radiopharmaceuticals) Market
  • Canada Nuclear Medicine (Radiopharmaceuticals) Market
  • Mexico Nuclear Medicine (Radiopharmaceuticals) Market
  • Europe Nuclear Medicine (Radiopharmaceuticals) Market
  • United Kingdom Nuclear Medicine (Radiopharmaceuticals) Market
  • Germany Nuclear Medicine (Radiopharmaceuticals) Market
  • France Nuclear Medicine (Radiopharmaceuticals) Market
  • Italy Nuclear Medicine (Radiopharmaceuticals) Market
  • Spain Nuclear Medicine (Radiopharmaceuticals) Market
  • Rest of Europe Nuclear Medicine (Radiopharmaceuticals) Market
  • Asia-Pacific Nuclear Medicine (Radiopharmaceuticals) Market
  • China Nuclear Medicine (Radiopharmaceuticals) Market
  • Japan Nuclear Medicine (Radiopharmaceuticals) Market
  • India Nuclear Medicine (Radiopharmaceuticals) Market
  • Australia Nuclear Medicine (Radiopharmaceuticals) Market
  • South Korea Nuclear Medicine (Radiopharmaceuticals) Market
  • Rest of Asia-Pacific Nuclear Medicine (Radiopharmaceuticals) Market
  • Rest of the World Nuclear Medicine (Radiopharmaceuticals) Market
  • South America Nuclear Medicine (Radiopharmaceuticals) Market
  • Middle East Nuclear Medicine (Radiopharmaceuticals) Market
  • Africa Nuclear Medicine (Radiopharmaceuticals) Market

Impact Analysis

AI-Powered Innovations and Applications:

The adoption of AI-powered innovations is significantly transforming the nuclear medicine (radiopharmaceuticals) market by enhancing both diagnostic accuracy and operational efficiency. AI algorithms are being integrated into imaging systems, such as PET and SPECT scanners, to improve image reconstruction, reduce noise, and detect abnormalities with higher precision, allowing clinicians to identify diseases at earlier stages. Additionally, AI facilitates automated workflow management, including patient scheduling, radiopharmaceutical dose calculation, and quality control, reducing human error and optimizing resource utilization. Moreover, AI applications in theranostics are enabling personalized treatment planning by analyzing large datasets to predict patient response to radiopharmaceutical therapies, such as targeted cancer treatments. The integration of AI also supports drug development, helping manufacturers design more effective radiotracers and accelerate regulatory approvals. Consequently, AI-driven innovations are improving clinical outcomes, reducing operational costs, and increasing the adoption of nuclear medicine procedures, thereby boosting the overall growth and efficiency of the nuclear medicine (radiopharmaceuticals) market.

U.S. Tariff Impact Analysis on Nuclear Medicine (Radiopharmaceuticals) Market:

The U.S. tariffs on imported medical equipment and radiopharmaceuticals have had a notable impact on the nuclear medicine (radiopharmaceuticals) market. Increased import duties on raw materials, isotopes, and diagnostic kits have raised the cost of production for domestic manufacturers relying on global supply chains. Additionally, higher costs are often passed on to healthcare providers, potentially limiting the adoption of advanced nuclear imaging and therapeutic procedures in cost-sensitive hospitals and clinics. Moreover, tariffs may prompt companies to invest in local manufacturing and supply chain diversification to reduce dependency on imports, which could increase initial capital expenditures but improve long-term market stability. Consequently, while tariffs may temporarily slow market growth due to higher prices, they also encourage strategic localization and innovation, shaping the competitive and operational landscape of the U.S. nuclear medicine (radiopharmaceuticals) market.

How This Analysis Helps Clients

  • Cost Management: By understanding the tariff landscape, clients can anticipate cost increases and adjust pricing strategies accordingly, ensuring profitability.
  • Supply Chain Optimization: Clients can identify alternative sourcing options and diversify their supply chains to reduce dependency on high-tariff regions, enhancing resilience.
  • Regulatory Navigation: Expert guidance on navigating the evolving regulatory environment helps clients maintain compliance and avoid potential legal challenges.
  • Strategic Planning: Insights into tariff impacts enable clients to make informed decisions about manufacturing locations, partnerships, and market entry strategies.

Key takeaways from the nuclear medicine (radiopharmaceuticals) market report study

  • Market size analysis for the current nuclear medicine (radiopharmaceuticals) market size (2025), and market forecast for 8 years (2026 to 2034)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
  • Key companies dominating the nuclear medicine (radiopharmaceuticals) market.
  • Various opportunities available for the other competitors in the nuclear medicine (radiopharmaceuticals) market space.
  • What are the top-performing segments in 2025? How these segments will perform in 2034?
  • Which are the top-performing regions and countries in the current nuclear medicine (radiopharmaceuticals) market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for the nuclear medicine (radiopharmaceuticals) market growth in the future?

Frequently Asked Questions for the Nuclear Medicine (Radiopharmaceuticals) Market

1. What is the growth rate of the nuclear medicine (radiopharmaceuticals) market?

  • The nuclear medicine (radiopharmaceuticals) market is estimated to grow at a CAGR of 9.50% during the forecast period from 2026 to 2034.

2. What is the market for nuclear medicine/ radiopharmaceuticals?

  • The global nuclear medicine (radiopharmaceuticals) market is expected to increase from USD 10,746.92 million in 2025 to USD 24,152.35 million by 2034, reflecting strong and sustained growth.

3. Which region has the highest share in the nuclear medicine (radiopharmaceuticals) market?

  • North America is projected to lead the global nuclear medicine (radiopharmaceuticals) market due to the rising prevalence of cancer, cardiovascular, and chronic diseases, driven by lifestyle changes and high processed food consumption. Additionally, the presence of major domestic players, a growing geriatric population, and favorable reimbursement policies for radiopharmaceuticals in the U.S. are key factors supporting market growth in the region.

4. What are the drivers for the nuclear medicine (radiopharmaceuticals) market?

  • The nuclear medicine (radiopharmaceuticals) market is witnessing strong growth due to the rising prevalence of cancer, cardiovascular, and chronic diseases, coupled with a growing geriatric population. Additionally, increasing demand for image-guided diagnostics and procedures, a robust pipeline of innovative products, and supportive government initiatives are driving adoption. Moreover, ongoing R&D activities, regulatory approvals, new product launches, and the presence of key industry players are further fueling market expansion, positioning nuclear medicine as a critical component of modern healthcare.

5. Who are the key players operating in the nuclear medicine (radiopharmaceuticals) market?

  • Some of the key market players operating in the nuclear medicine (radiopharmaceuticals) market include Lantheus, Cardinal Health, GE Healthcare, Curium Pharma, Pharmalogic Holdings Corp., Novartis, Cambridge Isotope Laboatories, Inc., Sotera Health LLC, Bracco Imaging SpA, Jubilant Pharma Limited, NECSA Ltd., IBA Radiopharma Solutions, Bayer AG, Norgine, NorthStar Medical Radioisotopes, LLC, Eckert & Ziegler, Telix Pharmaceuticals Limited, ITM Isotope Technologies Munich SE, Mallinckrodt PLC, ROTOP Pharmaka GmbH and others.

Table of Contents

1. Nuclear Medicine (Radiopharmaceuticals) Market Report Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Segmentation
  • 1.3 Market Assumption

2. Nuclear Medicine (Radiopharmaceuticals) Market Executive Summary

  • 2.1 Market at Glance

3. Nuclear Medicine (Radiopharmaceuticals) Market Key Factors Analysis

  • 3.1 Nuclear Medicine (Radiopharmaceuticals) Market Drivers
    • 3.1.1 Rising prevalence of cancer, cardiovascular, and other chronic diseases
    • 3.1.2 Increasing demand for targeted radiotherapy
    • 3.1.3 Growing adoption of PET and SPECT imaging
  • 3.2 Nuclear Medicine (Radiopharmaceuticals) Market Restraints and Challenges
    • 3.2.1 Short half-life, radiation exposure concerns, and high infrastructure and operational cost
    • 3.2.2 Stringent regulatory approval process
  • 3.3 Nuclear Medicine (Radiopharmaceuticals) Market Opportunity
    • 3.3.1 Rising research and development opportunities and presence of robust products in pipeline

4. Impact Analysis

  • 4.1 AI-Powered Innovations and Applications
  • 4.2 U.S. Tariff Impact Analysis

5. Regulatory Analysis

  • 5.1 The United States
  • 5.2 Europe
  • 5.3 Japan
  • 5.4 China

6. Nuclear Medicine (Radiopharmaceuticals) Market Porter's Five Forces Analysis

  • 6.1 Bargaining Power of Suppliers
  • 6.2 Bargaining Power of Consumers
  • 6.3 Threat of New Entrants
  • 6.4 Threat of Substitutes
  • 6.5 Competitive Rivalry

7. Nuclear Medicine (Radiopharmaceuticals) Market Assessment

  • 7.1 By Product Type
    • 7.1.1 Diagnostic Products
      • 7.1.1.1 Single Photon Emission Computed Tomography (SPECT)
      • 7.1.1.1.1 Technetium-99m
      • 7.1.1.1.2 Iodine-125
      • 7.1.1.1.3 Xenon-133
      • 7.1.1.1.4 Others
      • 7.1.1.2 Positron Emission Tomography (PET)
      • 7.1.1.2.1 Fluorine-18
      • 7.1.1.2.2 Carbon-11
      • 7.1.1.2.3 Gallium-68
      • 7.1.1.2.4 Others
    • 7.1.2 Therapeutics Products
      • 7.1.2.1 Alpha Emitters
      • 7.1.2.1.1 Astatine-211
      • 7.1.2.1.2 Actinium-225
      • 7.1.2.1.3 Lead-212
      • 7.1.2.1.4 Others
      • 7.1.2.2 Beta Emitters
      • 7.1.2.2.1 Lutetium-177
      • 7.1.2.2.2 Iodine-131
      • 7.1.2.2.3 Yttrium-90
      • 7.1.2.2.4 Others
      • 7.1.2.3 Brachytherapy
  • 7.2 By Application
    • 7.2.1 Cardiology
    • 7.2.2 Neurology
    • 7.2.3 Oncology
    • 7.2.4 Others
  • 7.3 By End-Users
    • 7.3.1 Hospitals
    • 7.3.2 Diagnostic Centers
    • 7.3.3 Others
  • 7.4 By Geography
    • 7.4.1 North America
      • 7.4.1.1 United States Nuclear Medicine (Radiopharmaceuticals) Market Size in USD million (2023-2034)
      • 7.4.1.2 Canada Nuclear Medicine (Radiopharmaceuticals) Market Size in USD million (2023-2034)
      • 7.4.1.3 Mexico Nuclear Medicine (Radiopharmaceuticals) Market Size in USD million (2023-2034)
    • 7.4.2 Europe
      • 7.4.2.1 France Nuclear Medicine (Radiopharmaceuticals) Market Size in USD million (2023-2034)
      • 7.4.2.2 Germany Nuclear Medicine (Radiopharmaceuticals) Market Size in USD million (2023-2034)
      • 7.4.2.3 United Kingdom Nuclear Medicine (Radiopharmaceuticals) Market Size in USD million (2023-2034)
      • 7.4.2.4 Italy Nuclear Medicine (Radiopharmaceuticals) Market Size in USD million (2023-2034)
      • 7.4.2.5 Spain Nuclear Medicine (Radiopharmaceuticals) Market Size in USD million (2023-2034)
      • 7.4.2.6 Rest of Europe Nuclear Medicine (Radiopharmaceuticals) Market Size in USD million (2023-2034)
    • 7.4.3 Asia-Pacific
      • 7.4.3.1 China Nuclear Medicine (Radiopharmaceuticals) Market Size in USD million (2023-2034)
      • 7.4.3.2 Japan Nuclear Medicine (Radiopharmaceuticals) Market Size in USD million (2023-2034)
      • 7.4.3.3 India Nuclear Medicine (Radiopharmaceuticals) Market Size in USD million (2023-2034)
      • 7.4.3.4 Australia Nuclear Medicine (Radiopharmaceuticals) Market Size in USD million (2023-2034)
      • 7.4.3.5 South Korea Nuclear Medicine (Radiopharmaceuticals) Market Size in USD million (2023-2034)
      • 7.4.3.6 Rest of Asia-Pacific Nuclear Medicine (Radiopharmaceuticals) Market Size in USD million (2023-2034)
    • 7.4.4 Rest of the World (RoW)
      • 7.4.4.1 Middle East Nuclear Medicine (Radiopharmaceuticals) Market Size in USD million (2023-2034)
      • 7.4.4.2 Africa Nuclear Medicine (Radiopharmaceuticals) Market Size in USD million (2023-2034)
      • 7.4.4.3 South America Nuclear Medicine (Radiopharmaceuticals) Market Size In USD Million (2023-2034)

8. Competitive Landscape

9. Nuclear Medicine (Radiopharmaceuticals) Market Company and Product Profiles

  • 9.1 Lantheus
    • 9.1.1 Company Overview
    • 9.1.2 Company Snapshot
    • 9.1.3 Financial Overview
    • 9.1.4 Product Listing
    • 9.1.5 Entropy
  • 9.2 Cardinal Health
    • 9.2.1 Company Overview
    • 9.2.2 Company Snapshot
    • 9.2.3 Financial Overview
    • 9.2.4 Product Listing
    • 9.2.5 Entropy
  • 9.3 GE Healthcare
    • 9.3.1 Company Overview
    • 9.3.2 Company Snapshot
    • 9.3.3 Financial Overview
    • 9.3.4 Product Listing
    • 9.3.5 Entropy
  • 9.4 Curium Pharma
    • 9.4.1 Company Overview
    • 9.4.2 Company Snapshot
    • 9.4.3 Financial Overview
    • 9.4.4 Product Listing
    • 9.4.5 Entropy
  • 9.5 Pharmalogic Holdings Corp.
    • 9.5.1 Company Overview
    • 9.5.2 Company Snapshot
    • 9.5.3 Financial Overview
    • 9.5.4 Product Listing
    • 9.5.5 Entropy
  • 9.6 Novartis
    • 9.6.1 Company Overview
    • 9.6.2 Company Snapshot
    • 9.6.3 Financial Overview
    • 9.6.4 Product Listing
    • 9.6.5 Entropy
  • 9.7 Cambridge Isotope Laboratories
    • 9.7.1 Company Overview
    • 9.7.2 Company Snapshot
    • 9.7.3 Financial Overview
    • 9.7.4 Product Listing
    • 9.7.5 Entropy
  • 9.8 Sotera Health
    • 9.8.1 Company Overview
    • 9.8.2 Company Snapshot
    • 9.8.3 Financial Overview
    • 9.8.4 Product Listing
    • 9.8.5 Entropy
  • 9.9 Bracco Imaging SpA
    • 9.9.1 Company Overview
    • 9.9.2 Company Snapshot
    • 9.9.3 Financial Overview
    • 9.9.4 Product Listing
    • 9.9.5 Entropy
  • 9.10 Jubilant Pharma Ltd.
    • 9.10.1 Company Overview
    • 9.10.2 Company Snapshot
    • 9.10.3 Financial Overview
    • 9.10.4 Product Listing
    • 9.10.5 Entropy
  • 9.11 NECSA Ltd.
    • 9.11.1 Company Overview
    • 9.11.2 Company Snapshot
    • 9.11.3 Financial Overview
    • 9.11.4 Product Listing
    • 9.11.5 Entropy
  • 9.12 IBA Radiopharma Solutions
    • 9.12.1 Company Overview
    • 9.12.2 Company Snapshot
    • 9.12.3 Financial Overview
    • 9.12.4 Product Listing
    • 9.12.5 Entropy
  • 9.13 Bayer AG
    • 9.13.1 Company Overview
    • 9.13.2 Company Snapshot
    • 9.13.3 Financial Overview
    • 9.13.4 Product Listing
    • 9.13.5 Entropy
  • 9.14 Norgine
    • 9.14.1 Company Overview
    • 9.14.2 Company Snapshot
    • 9.14.3 Financial Overview
    • 9.14.4 Product Listing
    • 9.14.5 Entropy
  • 9.15 NorthStar Medical Radioisotopes, LLC
    • 9.15.1 Company Overview
    • 9.15.2 Company Snapshot
    • 9.15.3 Financial Overview
    • 9.15.4 Product Listing
    • 9.15.5 Entropy
  • 9.16 Eckert & Ziegler
    • 9.16.1 Company Overview
    • 9.16.2 Company Snapshot
    • 9.16.3 Financial Overview
    • 9.16.4 Product Listing
    • 9.16.5 Entropy
  • 9.17 Telix Pharmaceuticals
    • 9.17.1 Company Overview
    • 9.17.2 Company Snapshot
    • 9.17.3 Financial Overview
    • 9.17.4 Product Listing
    • 9.17.5 Entropy
  • 9.18 ITM Isotope Technologies Munich SE
    • 9.18.1 Company Overview
    • 9.18.2 Company Snapshot
    • 9.18.3 Financial Overview
    • 9.18.4 Product Listing
    • 9.18.5 Entropy
  • 9.19 Mallinckrodt PLC
    • 9.19.1 Company Overview
    • 9.19.2 Company Snapshot
    • 9.19.3 Financial Overview
    • 9.19.4 Product Listing
    • 9.19.5 Entropy
  • 9.20 ROTOP Pharmaka GmbH
    • 9.20.1 Company Overview
    • 9.20.2 Company Snapshot
    • 9.20.3 Financial Overview
    • 9.20.4 Product Listing
    • 9.20.5 Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us

List of Tables

  • Table 1: Nuclear Medicine (Radiopharmaceuticals) Market in Global (2023-2034)
  • Table 2: Nuclear Medicine (Radiopharmaceuticals) Market in Global by Product Type (2023-2034)
  • Table 3: Nuclear Medicine (Radiopharmaceuticals) Market in Global by Application (2023-2034)
  • Table 4: Nuclear Medicine (Radiopharmaceuticals) Market in Global by End-Users (2023-2034)
  • Table 5: Nuclear Medicine (Radiopharmaceuticals) Market in Global by Geography (2023-2034)
  • Table 6: Nuclear Medicine (Radiopharmaceuticals) Market in North America (2023-2034)
  • Table 7: Nuclear Medicine (Radiopharmaceuticals) Market in the United States (2023-2034)
  • Table 8: Nuclear Medicine (Radiopharmaceuticals) Market in Canada (2023-2034)
  • Table 9: Nuclear Medicine (Radiopharmaceuticals) Market in Mexico (2023-2034)
  • Table 10: Nuclear Medicine (Radiopharmaceuticals) Market in Europe (2023-2034)
  • Table 11: Nuclear Medicine (Radiopharmaceuticals) Market in France (2023-2034)
  • Table 12: Nuclear Medicine (Radiopharmaceuticals) Market in Germany (2023-2034)
  • Table 13: Nuclear Medicine (Radiopharmaceuticals) Market in United Kingdom (2023-2034)
  • Table 14: Nuclear Medicine (Radiopharmaceuticals) Market in Italy (2023-2034)
  • Table 15: Nuclear Medicine (Radiopharmaceuticals) Market in Spain (2023-2034)
  • Table 16: Nuclear Medicine (Radiopharmaceuticals) Market in the Rest of Europe (2023-2034)
  • Table 17: Nuclear Medicine (Radiopharmaceuticals) Market in Asia-Pacific (2023-2034)
  • Table 18: Nuclear Medicine (Radiopharmaceuticals) Market in China (2023-2034)
  • Table 19: Nuclear Medicine (Radiopharmaceuticals) Market in Japan (2023-2034)
  • Table 20: Nuclear Medicine (Radiopharmaceuticals) Market in India (2023-2034)
  • Table 21: Nuclear Medicine (Radiopharmaceuticals) Market in Australia (2023-2034)
  • Table 22: Nuclear Medicine (Radiopharmaceuticals) Market in South Korea (2023-2034)
  • Table 23: Nuclear Medicine (Radiopharmaceuticals) Market in Rest of Asia-Pacific (2023-2034)
  • Table 24: Nuclear Medicine (Radiopharmaceuticals) Market in the Rest of the World (2023-2034)
  • Table 25: Nuclear Medicine (Radiopharmaceuticals) Market in the Middle East (2023-2034)
  • Table 26: Nuclear Medicine (Radiopharmaceuticals) Market in Africa (2023-2034)
  • Table 27: Nuclear Medicine (Radiopharmaceuticals) Market in South America (2023-2034)
  • Table 28: Competitive Landscape
  • Table 29: Startup Funding & Investment Trends

List of Figures

  • Figure 1: Nuclear Medicine (Radiopharmaceuticals) Market Drivers
  • Figure 2: Nuclear Medicine (Radiopharmaceuticals) Market Restraints
  • Figure 3: Nuclear Medicine (Radiopharmaceuticals) Market Opportunities
  • Figure 4: AI-Powered Innovations in Nuclear Medicine (Radiopharmaceuticals) Market
  • Figure 5: US Tariff Impact on Nuclear Medicine (Radiopharmaceuticals) Market
  • Figure 6: Regulatory Analysis (US, EU, Japan, China)
  • Figure 7: Porter's Five Forces Analysis
  • Figure 8: Competitive Analysis
  • Figure 9: Nuclear Medicine (Radiopharmaceuticals) Market in Global (2023-2034)
  • Figure 10: Nuclear Medicine (Radiopharmaceuticals) Market in Global by Product Type (2023-2034)
  • Figure 11: Nuclear Medicine (Radiopharmaceuticals) Market in Global by Application (2023-2034)
  • Figure 12: Nuclear Medicine (Radiopharmaceuticals) Market in Global by End-Users (2023-2034)
  • Figure 13: Nuclear Medicine (Radiopharmaceuticals) Market in Global by Geography (2023-2034)
  • Figure 14: Nuclear Medicine (Radiopharmaceuticals) Market in North America (2023-2034)
  • Figure 15: Nuclear Medicine (Radiopharmaceuticals) Market in the United States (2023-2034)
  • Figure 16: Nuclear Medicine (Radiopharmaceuticals) Market in Canada (2023-2034)
  • Figure 17: Nuclear Medicine (Radiopharmaceuticals) Market in Mexico (2023-2034)
  • Figure 18: Nuclear Medicine (Radiopharmaceuticals) Market in Europe (2023-2034)
  • Figure 19: Nuclear Medicine (Radiopharmaceuticals) Market in France (2023-2034)
  • Figure 20: Nuclear Medicine (Radiopharmaceuticals) Market in Germany (2023-2034)
  • Figure 21: Nuclear Medicine (Radiopharmaceuticals) Market in United Kingdom (2023-2034)
  • Figure 22: Nuclear Medicine (Radiopharmaceuticals) Market in Italy (2023-2034)
  • Figure 23: Nuclear Medicine (Radiopharmaceuticals) Market in Spain (2023-2034)
  • Figure 24: Nuclear Medicine (Radiopharmaceuticals) Market in the Rest of Europe (2023-2034)
  • Figure 25: Nuclear Medicine (Radiopharmaceuticals) Market in Asia-Pacific (2023-2034)
  • Figure 26: Nuclear Medicine (Radiopharmaceuticals) Market in China (2023-2034)
  • Figure 27: Nuclear Medicine (Radiopharmaceuticals) Market in Japan (2023-2034)
  • Figure 28: Nuclear Medicine (Radiopharmaceuticals) Market in India (2023-2034)
  • Figure 29: Nuclear Medicine (Radiopharmaceuticals) Market in Australia (2023-2034)
  • Figure 30: Nuclear Medicine (Radiopharmaceuticals) Market in South Korea (2023-2034)
  • Figure 31: Nuclear Medicine (Radiopharmaceuticals) Market in Rest of Asia-Pacific (2023-2034)
  • Figure 32: Nuclear Medicine (Radiopharmaceuticals) Market in the Rest of the World (2023-2034)
  • Figure 33: Nuclear Medicine (Radiopharmaceuticals) Market in the Middle East (2023-2034)
  • Figure 34: Nuclear Medicine (Radiopharmaceuticals) Market in Africa (2023-2034)
  • Figure 35: Nuclear Medicine (Radiopharmaceuticals) Market in South America (2023-2034)
  • Figure 36: Competitive Landscape
  • Figure 37: Startup Funding & Investment Trends